United Therapeutics Corporation Investing Cash Flow
United Therapeutics Corporation (UTHR) reported Investing Cash Flow of $831.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- United Therapeutics Corporation net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $87.50M.
- United Therapeutics Corporation net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $743.70M.
- United Therapeutics Corporation net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$227.60M.
- United Therapeutics Corporation net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $140.90M.
- United Therapeutics Corporation net cash provided by (used in) investing activities for fiscal 2025 was -$551.30M, a 232.14% decline from fiscal 2024.
- United Therapeutics Corporation net cash provided by (used in) investing activities for fiscal 2024 was $417.20M.
- United Therapeutics Corporation net cash provided by (used in) investing activities for fiscal 2023 was -$719.60M.
- United Therapeutics Corporation net cash provided by (used in) investing activities for fiscal 2022 was -$811.50M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $87.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $831.20M 10-Q · filed 2026-08-05 | $603.60M derived: sum of 3 quarters · filed 2026-08-05 | $744.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $743.70M 10-Q · filed 2026-05-06 | $516.10M derived: sum of 2 quarters · filed 2026-05-06 | $657.00M derived: sum of 3 quarters · filed 2026-05-06 | $357.10M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$227.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$86.70M derived: sum of 2 quarters · filed 2026-02-25 | -$386.60M derived: sum of 3 quarters · filed 2026-08-05 | -$551.30M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $140.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$159.00M derived: sum of 2 quarters · filed 2026-08-05 | -$323.70M 10-Q · filed 2025-10-29 | -$446.90M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$299.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$464.60M 10-Q · filed 2026-08-05 | -$587.80M derived: sum of 3 quarters · filed 2026-08-05 | -$702.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$164.70M 10-Q · filed 2026-05-06 | -$287.90M derived: sum of 2 quarters · filed 2026-05-06 | -$402.80M derived: sum of 3 quarters · filed 2026-05-06 | -$482.80M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$123.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$238.10M derived: sum of 2 quarters · filed 2026-02-25 | -$318.10M derived: sum of 3 quarters · filed 2026-02-25 | $417.20M 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$114.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$194.90M derived: sum of 2 quarters · filed 2025-10-29 | $540.40M 10-Q · filed 2025-10-29 | $582.50M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | -$80.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $655.30M 10-Q · filed 2025-07-30 | $697.40M derived: sum of 3 quarters · filed 2026-02-25 | $384.00M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $735.30M 10-Q · filed 2025-04-30 | $777.40M derived: sum of 2 quarters · filed 2026-02-25 | $464.00M derived: sum of 3 quarters · filed 2026-02-25 | $236.80M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $42.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$271.30M derived: sum of 2 quarters · filed 2026-02-25 | -$498.50M derived: sum of 3 quarters · filed 2026-02-25 | -$719.60M 10-K · filed 2026-02-25 | |
| 2023-09-30 | -$313.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$540.60M derived: sum of 2 quarters · filed 2024-10-30 | -$761.70M 10-Q · filed 2024-10-30 | -$951.00M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | -$227.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$448.30M 10-Q · filed 2024-07-31 | -$637.60M derived: sum of 3 quarters · filed 2025-02-26 | -$731.60M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | -$221.10M 10-Q · filed 2024-05-01 | -$410.40M derived: sum of 2 quarters · filed 2025-02-26 | -$504.40M derived: sum of 3 quarters · filed 2025-02-26 | -$673.40M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | -$189.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$283.30M derived: sum of 2 quarters · filed 2025-02-26 | -$452.30M derived: sum of 3 quarters · filed 2025-02-26 | -$811.50M 10-K · filed 2025-02-26 | |
| 2022-09-30 | -$94.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$263.00M derived: sum of 2 quarters · filed 2023-11-01 | -$622.20M 10-Q · filed 2023-11-01 | -$818.00M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | -$169.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$528.20M 10-Q · filed 2023-08-02 | -$724.00M derived: sum of 3 quarters · filed 2024-02-21 | -$959.90M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | -$359.20M 10-Q · filed 2023-05-03 | -$555.00M derived: sum of 2 quarters · filed 2024-02-21 | -$790.90M derived: sum of 3 quarters · filed 2024-02-21 | -$839.80M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | -$195.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$431.70M derived: sum of 2 quarters · filed 2024-02-21 | -$480.60M derived: sum of 3 quarters · filed 2024-02-21 | -$486.90M 10-K · filed 2024-02-21 | |
| 2021-09-30 | -$235.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$284.80M derived: sum of 2 quarters · filed 2022-11-02 | -$291.10M 10-Q · filed 2022-11-02 | -$354.90M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | -$48.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$55.20M 10-Q · filed 2022-08-03 | -$119.00M derived: sum of 3 quarters · filed 2023-02-22 | -$390.70M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | -$6.30M 10-Q · filed 2022-05-04 | -$70.10M derived: sum of 2 quarters · filed 2023-02-22 | -$341.80M derived: sum of 3 quarters · filed 2023-02-22 | -$717.20M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | -$63.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$335.50M derived: sum of 2 quarters · filed 2023-02-22 | -$710.90M derived: sum of 3 quarters · filed 2023-02-22 | -$738.50M 10-K · filed 2023-02-22 | |
| 2020-09-30 | -$271.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$647.10M derived: sum of 2 quarters · filed 2021-11-03 | -$674.70M 10-Q · filed 2021-11-03 | -$608.50M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | -$375.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$403.00M 10-Q · filed 2021-08-04 | -$336.80M derived: sum of 3 quarters · filed 2022-02-24 | -$635.50M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$27.60M 10-Q · filed 2021-05-05 | $38.60M derived: sum of 2 quarters · filed 2022-02-24 | -$260.10M derived: sum of 3 quarters · filed 2022-02-24 | -$302.70M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $66.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$232.50M derived: sum of 2 quarters · filed 2022-02-24 | -$275.10M derived: sum of 3 quarters · filed 2022-02-24 | -$335.40M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$298.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | -$341.30M derived: sum of 2 quarters · filed 2020-10-28 | -$401.60M 10-Q · filed 2020-10-28 | -$473.80M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | -$42.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$102.90M 10-Q · filed 2020-07-29 | -$175.10M derived: sum of 3 quarters · filed 2021-02-24 | -$505.00M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | -$60.30M 10-Q · filed 2020-04-29 | -$132.50M derived: sum of 2 quarters · filed 2021-02-24 | -$462.40M derived: sum of 3 quarters · filed 2021-02-24 | -$822.20M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | -$72.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$402.10M derived: sum of 2 quarters · filed 2021-02-24 | -$761.90M derived: sum of 3 quarters · filed 2021-02-24 | -$820.60M 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$329.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$689.70M derived: sum of 2 quarters · filed 2019-10-30 | -$748.40M 10-Q · filed 2019-10-30 | -$715.40M 10-Q · filed 2018-10-31 | -$1.03B derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$359.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$418.50M 10-Q · filed 2019-07-31 | -$696.90M derived: sum of 3 quarters · filed 2020-02-26 | -$897.10M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | -$58.70M 10-Q · filed 2019-05-01 | -$337.10M derived: sum of 2 quarters · filed 2020-02-26 | -$537.30M derived: sum of 3 quarters · filed 2020-02-26 | -$728.70M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | -$278.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$478.60M derived: sum of 2 quarters · filed 2020-02-26 | -$670.00M derived: sum of 3 quarters · filed 2020-02-26 | -$835.60M 10-K · filed 2020-02-26 | |
| 2017-09-30 | -$200.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$391.60M derived: sum of 2 quarters · filed 2018-10-31 | -$557.20M 10-Q · filed 2018-10-31 | -$548.70M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | -$191.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$357.00M 10-Q · filed 2018-08-01 | -$348.50M derived: sum of 3 quarters · filed 2019-02-27 | -$328.40M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | -$165.60M 10-Q · filed 2018-05-02 | -$157.10M derived: sum of 2 quarters · filed 2019-02-27 | -$137.00M derived: sum of 3 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $28.60M derived: sum of 2 quarters · filed 2019-02-27 | $48.30M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | $20.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $39.80M 10-Q · filed 2017-10-25 | |||
| 2016-06-30 | $19.70M 10-Q · filed 2017-07-27 | ||||
| 2015-12-31 | $503.60M 10-K · filed 2018-02-21 | ||||
| 2012-12-31 | -$164.70M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$117.08M derived: sum of 2 quarters · filed 2013-02-26 | -$117.37M derived: sum of 3 quarters · filed 2013-02-26 | -$163.36M 10-K · filed 2013-02-26 | |
| 2012-09-30 | $47.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $47.33M derived: sum of 2 quarters · filed 2012-11-01 | $1.34M 10-Q · filed 2012-11-01 | $17.51M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2012-06-30 | -$287.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | -$46.28M 10-Q · filed 2012-07-26 | -$30.10M derived: sum of 3 quarters · filed 2013-02-26 | -$88.06M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2012-03-31 | -$45.99M 10-Q · filed 2012-04-26 | -$29.82M derived: sum of 2 quarters · filed 2013-02-26 | -$87.78M derived: sum of 3 quarters · filed 2013-02-26 | -$131.99M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-12-31 | $16.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$41.79M derived: sum of 2 quarters · filed 2013-02-26 | -$86.00M derived: sum of 3 quarters · filed 2013-02-26 | -$121.33M 10-K · filed 2013-02-26 | |
| 2011-09-30 | -$57.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$102.17M derived: sum of 2 quarters · filed 2012-11-01 | -$137.51M 10-Q · filed 2012-11-01 | -$200.82M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | -$44.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | -$79.55M 10-Q · filed 2012-07-26 | -$142.86M derived: sum of 3 quarters · filed 2013-02-26 | -$333.94M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | -$35.34M 10-Q · filed 2012-04-26 | -$98.65M derived: sum of 2 quarters · filed 2013-02-26 | -$289.73M derived: sum of 3 quarters · filed 2013-02-26 | -$252.80M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$63.31M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$254.39M derived: sum of 2 quarters · filed 2013-02-26 | -$217.46M derived: sum of 3 quarters · filed 2013-02-26 | -$209.24M 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$191.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$154.15M derived: sum of 2 quarters · filed 2011-10-27 | -$145.92M 10-Q · filed 2011-10-27 | -$213.96M derived: sum of 4 quarters · filed 2012-02-28 | |
| 2010-06-30 | $36.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $45.15M 10-Q · filed 2011-07-28 | -$22.88M derived: sum of 3 quarters · filed 2012-02-28 | -$56.48M derived: sum of 4 quarters · filed 2012-02-28 | |
| 2010-03-31 | $8.23M 10-Q · filed 2011-04-28 | -$59.80M derived: sum of 2 quarters · filed 2012-02-28 | -$93.41M derived: sum of 3 quarters · filed 2012-02-28 | ||
| 2009-12-31 | -$68.03M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | -$101.63M derived: sum of 2 quarters · filed 2012-02-28 | -$162.62M 10-K · filed 2012-02-28 | ||
| 2009-09-30 | -$33.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$94.59M 10-Q · filed 2010-10-28 | |||
| 2009-06-30 | -$60.99M 10-Q · filed 2010-07-28 | ||||
| 2008-12-31 | -$181.24M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |